Published in Int J Mol Med on May 01, 1998
Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol (2008) 1.05
Assays for detection of telomerase activity. Acta Naturae (2011) 0.77
Biosensor Techniques Used for Determination of Telomerase Activity in Cancer Cells. Sensors (Basel) (2008) 0.75
C-reactive protein and coronary heart disease: a critical review. J Intern Med (2008) 2.25
Characterization of a transplantable adenocarcinoma of the mouse colon producing cachexia in recipient animals. J Natl Cancer Inst (1987) 2.02
Diagnosis of Gerstmann-Sträussler syndrome in familial dementia with prion protein gene analysis. Lancet (1989) 1.97
Effect of mitral regurgitation on left ventricular thrombus formation in dilated cardiomyopathy. Am Heart J (1998) 1.93
Inherited prion disease with 144 base pair gene insertion. 1. Genealogical and molecular studies. Brain (1992) 1.86
In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer (1999) 1.47
Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid). Br J Cancer (1987) 1.47
Inhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma. Ann Allergy Asthma Immunol (1999) 1.46
An examination of linkage of schizophrenia and schizoaffective disorder to the pseudoautosomal region (Xp22.3) Br J Psychiatry (1994) 1.46
A critical appraisal of the predictive value of in vitro chemosensitivity assays. J Natl Cancer Inst (1990) 1.38
Synthesis and cytotoxicity of shikimate analogues. Structure:activity studies based on 1-crotonyloxymethyl-3R,4R,5R-trihydroxycyclohex-2-enone. Anticancer Drug Des (1992) 1.38
Antimicrobial activity of cecropins. J Antimicrob Chemother (1996) 1.31
Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs. Cancer Res (1998) 1.29
Pharmacokinetics and anti-tumour activity of LM985 in mice bearing transplantable adenocarcinomas of the colon. Br J Cancer (1986) 1.24
Preliminary experimental anticancer activity of cecropins. Pept Res (1995) 1.20
Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma. J Allergy Clin Immunol (1999) 1.15
Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol (2000) 1.14
Synthesis and antitumour activity of new derivatives of flavone-8-acetic acid (FAA). Part 3: 2-Heteroaryl derivatives. Arch Pharm (Weinheim) (1998) 1.13
EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer (1993) 1.13
Expression of HIF-1alpha and Glut-1 in human bladder cancer. Oncol Rep (2005) 1.12
In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity. Br J Cancer (1992) 1.11
Combined salmeterol 50 microg and fluticasone propionate 250 microg in the diskus device for the treatment of asthma. Am J Respir Crit Care Med (2000) 1.10
Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant (2009) 1.10
An in-frame insertion in the prion protein gene in familial Creutzfeldt-Jakob disease. Brain Res Mol Brain Res (1990) 1.09
IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther (2007) 1.07
Measurement of d sigma/dM and forward-backward charge asymmetry for high-mass Drell-Yan e(+)e(-) pairs from pp macro collisions at square root of s = 1.8 TeV. Phys Rev Lett (2001) 1.02
Efficacy of inhaled fluticasone propionate in asthma results from topical and not from systemic activity. Am J Respir Crit Care Med (1997) 1.00
Continuous caudal epidural analgesia for congenital lobar emphysema: a report of three cases. Anesth Analg (2001) 0.99
Pulsatile perfusion reduces the incidence of delayed graft function in expanded criteria donor kidney transplantation. Am J Transplant (2006) 0.98
Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer (1995) 0.97
Fluticasone propionate powder: oral corticosteroid-sparing effect and improved lung function and quality of life in patients with severe chronic asthma. J Allergy Clin Immunol (1999) 0.97
Time to onset of effect of fluticasone propionate in patients with asthma. J Allergy Clin Immunol (1999) 0.97
Calcineurin-inhibitor-free immunosuppression based on the JAK inhibitor CP-690,550: a pilot study in de novo kidney allograft recipients. Am J Transplant (2009) 0.95
Measurement of the strong coupling constant from inclusive jet production at the Tevatron pp collider. Phys Rev Lett (2002) 0.94
Therapeutic index: a vital component in selection of anticancer agents for clinical trial. J Natl Cancer Inst (1989) 0.94
Establishment and characterisation of new cell lines from human breast tumours initially established as tumour xenografts in NMRI nude mice. Breast Cancer Res Treat (1997) 0.94
Flavone acetic acid--an interesting novel therapeutic agent or just another disappointment? Br J Cancer (1991) 0.93
Search for gluinos and scalar quarks in pp collisions at square root[s] = 1.8 TeV using the missing energy plus multijets signature. Phys Rev Lett (2002) 0.93
EO9: relationship between DT-diaphorase levels and response in vitro and in vivo. Br J Cancer (1995) 0.93
Telomerase activity in normal and malignant mammalian tissues: feasibility of telomerase as a target for cancer chemotherapy. Br J Cancer (1997) 0.93
Bayesian methods for meta-analysis of causal relationships estimated using genetic instrumental variables. Stat Med (2010) 0.93
High dose DBMC associated tolerance in live-related renal allograft recipients. Transplant Proc (2000) 0.93
Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res (2000) 0.93
High through put 16S rRNA gene-based pyrosequencing analysis of the fecal microbiota of high FCR and low FCR broiler growers. Mol Biol Rep (2012) 0.93
Insertions in the prion protein gene in atypical dementias. Exp Neurol (1991) 0.92
Characterisation of the vasculature within a murine adenocarcinoma growing in different sites to evaluate the potential of vascular therapies. Acta Oncol (1995) 0.91
DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas. Eur J Cancer (1992) 0.90
Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice. Cancer Res (1989) 0.90
The influence of hydralazine on the vasculature, blood perfusion and chemosensitivity of MAC tumours. Br J Cancer (1992) 0.89
Lymphocyte enzyme activities in immunodeficiency syndromes with particular reference to common variable hypogammaglobulinaemia. Clin Exp Immunol (1983) 0.88
Serum neopterin patients with X-linked and acquired 'common variable' hypogammaglobulinaemia. Int Arch Allergy Appl Immunol (1989) 0.88
Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo. Br J Cancer (2003) 0.88
Variants of ADRA2A are associated with fasting glucose, blood pressure, body mass index and type 2 diabetes risk: meta-analysis of four prospective studies. Diabetologia (2011) 0.88
Factors associated with discard of recovered kidneys. Transplant Proc (2008) 0.87
Synthesis, mechanism of action, and biological evaluation of mitosenes. J Med Chem (1989) 0.86
Experimental correlations of in vitro drug sensitivity with in vivo responses to ThioTEPA in a panel of murine colon tumours. Cancer Chemother Pharmacol (1988) 0.86
Novel anti-tumour activity of 2,3,5-trimethyl-6-(3-pyridylmethyl)-1,4- benzoquinone (CV-6504) against established murine adenocarcinomas (MAC). Br J Cancer (1996) 0.86
Effects of routes of administration of TCNU on its plasma, tissue and tumour concentrations. Eur J Cancer Clin Oncol (1988) 0.86
Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids. Eur J Cancer (1997) 0.86
Studies on the kinetic properties and subcellular localization of adenine nucleotide phosphatases in peripheral blood lymphocytes from control subjects and patients with common variable primary hypogammaglobulinaemia. Clin Exp Immunol (1982) 0.86
Kidney transplantation in children and adolescents: an analysis of United Network for Organ Sharing Database. Transplant Proc (2009) 0.85
Effects of nandrolone decanoate on the toxicity and anti-tumour action of CCNU and FU in murine tumours. Br J Cancer (1981) 0.85
Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br J Cancer (2001) 0.85
Adult height, coronary heart disease and stroke: a multi-locus Mendelian randomization meta-analysis. Int J Epidemiol (2015) 0.85
Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent. Br J Cancer (2000) 0.84
Activity of N-[N'-(2-chloroethyl)-N'-nitrosocarbamoyl]-alanine and derivatives against transplantable adenocarcinomata of the mouse colon (MAC). J Cancer Res Clin Oncol (1986) 0.84
Enzyme analysis and subcellular fractionation of human peripheral blood lymphocytes with special reference to the localization of putative plasma membrane enzymes. Cell Biochem Funct (1983) 0.84
Kinetic properties of 5' nucleotidase in blood lymphocytes from healthy subjects, immunodeficient patients and cord blood. Clin Exp Immunol (1984) 0.84
Automated enzymic, protein and DNA microanalysis to tissue biopsy samples and subcellular fractions. Clin Chim Acta (1984) 0.84
Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice. Biochem Pharmacol (2000) 0.83
Heterogeneity of O6-alkylguanine DNA-alkyltransferase expression in human breast tumours. Br J Cancer (2002) 0.83
Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer. Br J Cancer (1996) 0.83
A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9. Br J Cancer (2001) 0.83
Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311. Br J Cancer (1999) 0.83
Treatment of multidrug-resistant tuberculosis in a remote, conflict-affected area of the Democratic Republic of Congo. Int J Tuberc Lung Dis (2012) 0.82
Combretastatin A-1 phosphate a novel tubulin-binding agent with in vivo anti vascular effects in experimental tumours. Anticancer Res (2002) 0.82
Preclinical pharmacology of the pyrrolobenzodiazepine (PBD) monomer DRH-417 (NSC 709119). J Chemother (2007) 0.82
The effect of 5,6-dimethylxanthenone-4-acetic acid on tumour necrosis factor production by human immune cells. Anticancer Res (1997) 0.81
Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-1 phosphate. Anticancer Res (2003) 0.81
Delayed presentation of paediatric penile constrictive band injury. Br J Plast Surg (2003) 0.81
Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1. Clin Cancer Res (1999) 0.81
Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9. Br J Pharmacol (2002) 0.81
Mega dose unfractionated donor bone marrow-derived cell infusion in thymus and periphery-an integrated clinical approach for tolerance in living related renal allografts. Transplant Proc (2003) 0.80
Uptake of free adenosine and adenosine from adenosine monophosphate by human peripheral blood lymphocytes: possible kinetic role for ecto-5'-nucleotidase in the regulation of intracellular adenosine. Clin Exp Immunol (1986) 0.80
Ultrasound in urological emergency: results of self audit and implications for training. Int Urol Nephrol (1996) 0.80
Can machine perfusion decrease the likelihood of discard among biopsied kidneys? Transplant Proc (2008) 0.80
Synthesis, DNA binding, footprinting and in vitro antitumour studies of a meta-hydroxy analogue of Hoechst 33258. Anticancer Drug Des (1995) 0.80
Importance of selected inhaler characteristics and acceptance of a new breath-actuated powder inhalation device. J Asthma (1997) 0.80
Characterisation and chemosensitivity of a well-differentiated murine transplantable adenocarcinoma of the colon. Br J Cancer (1983) 0.80
Identification of candidate sialome components expressed in ixodid tick salivary glands using secretion signal complementation in mammalian cells. Insect Mol Biol (2005) 0.80
Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. Eur Urol (2002) 0.79
On the distinction of suicide ideation versus attempt in elderly psychiatric inpatients. Gerontologist (1994) 0.79
Seminal vesicle cyst, renal agenesis and epididymitis in a 50-year-old patient. Br J Urol (1992) 0.79
Mature cystic teratoma of the sigmoid colon. Ultrasound Obstet Gynecol (2011) 0.79
High-performance liquid chromatographic analysis of AQ4N, an alkylaminoanthraquinone N-oxide. J Chromatogr B Biomed Sci Appl (2000) 0.79
Studies on the kinetic properties and subcellular localization of adenosine diphosphatase activity in human peripheral blood lymphocytes. Clin Exp Immunol (1981) 0.79
Antineoplastic activity of alkylphosphocholines (APC) in human breast carcinomas in vivo and in vitro; use of liposomes. Breast Cancer Res Treat (1994) 0.79
Nucleoside analogues: 8. Some isomers of B.3839, the original 5-fluorouracil/nitrosourea molecular combination, and their effect on colon, breast and lung tumours in mice. Anticancer Drug Des (1989) 0.79
Quantitative methods for assessing the effects of some anticancer drugs on mouse spermatogenesis. Arch Toxicol Suppl (1987) 0.79